系统性红斑狼疮治疗启动后疾病演变轨迹:四项贝利尤单抗临床试验结果
该研究对四项贝利尤单抗随机对照试验(BLISS-52、BLISS-76、BLISS-SC、EMBRACE)中2868例系统性红斑狼疮(SLE)患者进行事后分析,采用增长混合模型识别疾病演变轨迹。研究识别出四种轨迹:高活动度应答者、高活动度无应答者、中度活动度应答者、中度活动度无应答者;狼疮低疾病活动状态(LLDAS)和SLE缓解定义(DORIS)缓解达成与这些潜在类别相关。
要点
- 在四项贝利尤单抗试验的2868例SLE患者中,增长混合模型识别出四种疾病演变轨迹。
- 四种轨迹为高活动度应答者、高活动度无应答者、中度活动度应答者、中度活动度无应答者。
- LLDAS和DORIS缓解达成与上述潜在类别相关;单一临床变量无法预测疾病进展。
核心结论
- 通过将疾病活动度指标与患者报告结局(PROs)关联,识别出SLE治疗启动后四种不同的疾病演变轨迹。
- 该分类可能有助于个体化治疗和指导旨在区分不同预期治疗反应患者的生物学研究,因为没有任何单一临床变量能预测疾病进展。
研究设计与样本
- 四项贝利尤单抗随机对照试验(BLISS-52、BLISS-76、BLISS-SC、EMBRACE)的事后分析。
- 纳入至少2次访视且有SLEDAI-2K、BILAG、PGA、FACIT-F和糖皮质激素使用数据的患者,共分析2868例。
- 采用增长混合模型识别潜在类别。
主要发现
- 基线中位疾病病程4.5年(四分位距:1.5-9.7年),平均(±标准差)SDI 0.7(±2.0)、SLEDAI-2K 10.2(±3.6)、BILAG 17.0(±7.8)、PGA 1.5(±0.5)、FACIT-F 30.6(±11.9)、泼尼松剂量11.0(±8.9)mg/天。
- 初始模型中糖皮质激素使用和剂量产生高标准误,提示与潜在过程关联较弱。
- 精炼模型仅考虑临床指标和FACIT-F,并校正干预和SDI;无其他协变量改善拟合。
- 四种类别最佳描述疾病演变:高活动度应答者、高活动度无应答者、中度活动度应答者、中度活动度无应答者。
- LLDAS和DORIS缓解达成与潜在类别相关。
关键数值与推荐
- SLEDAI-2K基线均值10.2(±3.6)。
- BILAG基线均值17.0(±7.8)。
- PGA基线均值1.5(±0.5)。
- FACIT-F基线均值30.6(±11.9)。
- 泼尼松剂量基线均值11.0(±8.9)mg/天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 初始模型中糖皮质激素使用和剂量产生高标准误,提示与潜在过程关联较弱。
- 原文结论指出没有任何单一临床变量能预测疾病进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Upon commencement of therapy for active disease, patients with systemic lupus erythematosus (SLE) show varying evolution regarding disease activity measures and patient-reported outcomes (PROs). Our objective was to identify disease evolution trajectories to gain a deeper understanding of SLE progression, ultimately improving future trial design. METHODS: Patients with ≥2 visits and available data on Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), British Isles Lupus Assessment Group (BILAG), Physician Global Assessment (PGA), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), and glucocorticoid use were included in a post hoc analysis of four randomized controlled trials of belimumab (BLISS-52, BLISS-76, BLISS-SC, EMBRACE). Growth mixture modelling identified latent classes. RESULTS: Among 2868 patients analysed, baseline median disease duration was 4.5 (interquartile range: 1.5-9.7) years and mean (±standard deviation) Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index (SDI) 0.7 (±2.0), SLEDAI-2K 10.2 (±3.6), BILAG 17.0 (±7.8), PGA 1.5 (±0.5), FACIT-F 30.6 (±11.9) and prednisone dose 11.0 (±8.9) mg/day. In the initial model, glucocorticoid use and dose yielded high standard errors, indicating a weak link with the latent process. A refined model considered only clinical measures and FACIT-F, corrected for intervention and SDI; no other covariates improved the fit. Four classes best described disease evolution: highly active, responders; highly active, non-responders; moderately active, responders; moderately active, non-responders. Lupus Low Disease Activity State and Definitions of Remission in SLE remission attainment associated with latent classes. CONCLUSION: By linking disease activity measures with PROs, we identified four distinct trajectories describing SLE evolution following the initiation of therapy. This classification could be valuable for personalizing treatment and guiding biological studies aimed at distinguishing patients with varying anticipated treatment responses, as no single clinical variable alone can predict disease progression.
引用
- Parodis I, Lindblom J, Tsoi A, et al. Trajectories of disease evolution upon treatment initiation in systemic lupus erythematosus: results from four clinical trials of belimumab. Rheumatology (Oxford). 2025. PMID: 39412507. doi:10.1093/rheumatology/keae575
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。